Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris

被引:146
|
作者
Chams-Davatchi, Cheyda
Esmaili, Nafiseh
Daneshpazhooh, Maryam
Valikhani, Mahin
Balighi, Kamran
Hallaji, Zahra
Barzegari, Masoumeh
Akhyani, Maryam
Ghodsi, S. Zahra
Seirafi, Hassan
Tabrizi, Mohammad-Javad Nazemi
Mortazavi, Hossein
Mirshams-Shahshahani, Mostafa
机构
[1] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Tehran 11996, Iran
[2] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Pemphigus Res Unit, Tehran, Iran
关键词
D O I
10.1016/j.jaad.2007.05.024
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Pemphigus is a severe autoimmune blistering disease affecting the skin and mucosa. Mortality is high in the absence of treatment. Nowadays, treatment is based mainly on corticosteroids and cytotoxic drugs; however, because of the rarity of the disease worldwide, there is not yet a standard treatment based on randomized controlled trials, and the treatment used is based mainly on the experience of experts. Objective: The aim of this study was to compare the efficacy and safety of 4 treatment regimens for pemphigus vulgaris: prednisolone alone, prednisolone plus azathioprine, prednisolone plus mycophenolate mofetil, and prednisolone plus intravenous cyclophosphamide pulse therapy. Methods: One hundred twenty new cases of pemphigus vulgaris were enrolled. These patients were randomly allocated into 1 of 4 treatment groups (each comprising 30 patients) and received prednisolone (P), prednisolone and azathioprine (P/A), prednisolone and mycophenolate mofetil (P/MM), and prednisolone and intravenous cyclophosphamide pulse therapy (P/PC). They were followed up for I year at the Pemphigus Research Unit. Results: In groups P, P/A, P/MM, and P/PC, 23 (76.5%), 24 (80%), 21 (70%), and 22 (73.3%) of the patients, respectively, followed the regimen for the full 1-year period. The mean total dose of prednisolone administered in groups P, P/A, P/MM, and P/PC was 11631 mg (standard deviation [SD] = 7742), 7712 mg (SD = 955), 9798 mg (SD = 3995), and 8276 mg (SD = 810), respectively. The mean total dose of prednisolone in group P (prednisolone alone) was 11,631 mg, The mean total dose of prednisolone in the 3 cytotoxic groups was 8652 mg. By using analysis of variance, the difference was statistically significant (P =.047). in the cytotoxic groups, there was a significant difference between the P/A and P/MM groups (P =.007), but not between P/A and P/PC (P =.971), and P/MM and P/PC (P =.670). Side effects were not significantly different among the 4 groups. Limitations: Larger sample sizes and blind design are suggested for future studies. Conclusion. The efficacy of prednisolone is enhanced when it is combined with a cytotoxic drug. The most efficacious cytotoxic drug to reduce steroid was found to be azathioprine, followed by cyclophosphamide (pulse therapy), and mycoplienolate mofetil.
引用
收藏
页码:622 / 628
页数:7
相关论文
共 50 条
  • [31] Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized Controlled Trial
    Kelley, John M.
    Kaptchuk, Ted J.
    Cusin, Cristina
    Lipkin, Samuel
    Fava, Maurizio
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2012, 81 (05) : 312 - 314
  • [32] Open-Label Placebo Treatment for Cancer-Related Fatigue: A Randomized-Controlled Clinical Trial
    Hoenemeyer, Teri W.
    Kaptchuk, Ted J.
    Mehta, Tapan S.
    Fontaine, Kevin R.
    SCIENTIFIC REPORTS, 2018, 8
  • [33] Gatifloxacin Versus Ofloxacin for the Treatment of Uncomplicated Enteric Fever in Nepal: An Open-Label, Randomized, Controlled Trial
    Koirala, Samir
    Basnyat, Buddha
    Arjyal, Amit
    Shilpakar, Olita
    Shrestha, Kabina
    Shrestha, Rishav
    Shrestha, Upendra Man
    Agrawal, Krishna
    Koirala, Kanika Deshpande
    Thapa, Sudeep Dhoj
    Karkey, Abhilasha
    Dongol, Sabina
    Giri, Abhishek
    Shakya, Mila
    Pathak, Kamal Raj
    Campbell, James
    Baker, Stephen
    Farrar, Jeremy
    Wolbers, Marcel
    Dolecek, Christiane
    PLOS NEGLECTED TROPICAL DISEASES, 2013, 7 (10):
  • [34] Autoinoculation versus 35% trichloroacetic acid for the treatment of molluscum contagiosum: An open-label randomized controlled trial
    Saraswat, Shweta
    Choudhary, Paras
    Joshi, Yogi R.
    Yadav, Chinmai
    Kachhawa, Dilip
    Choudhary, Durga
    Singh, Harshvardhan
    TURK DERMATOLOJI DERGISI-TURKISH JOURNAL OF DERMATOLOGY, 2022, 16 (01): : 16 - 22
  • [35] The effectiveness of montelukast as adjunct treatment among children with atopic dermatitis: An open-label, randomized controlled trial
    Goh, A.
    Lowe, A.
    Zallmann, M.
    Su, J.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 52 - 52
  • [36] RIFAXIMIN TREATMENT IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS; A MULTICENTER, OPEN-LABEL, PILOT RANDOMIZED CONTROLLED TRIAL
    Song, Do Seon
    Yang, Jin Mo
    Jung, Young Kul
    Yim, Hyung-Joon
    Kim, Hee Yeon
    Kim, Chang Wook
    Kim, Soon Sun
    Cheong, Jae Youn
    Lee, Hae Lim
    Lee, Sung Won
    Yoo, Jeong-Ju
    Kim, Sang Gyune
    Kim, Young Seok
    HEPATOLOGY, 2021, 74 : 250A - 250A
  • [37] Topiramate in Lennox-Gastaut syndrome: Open-label treatment of patients completing a randomized controlled trial
    Glauser, TA
    Levisohn, PM
    Ritter, F
    Sachdeo, RC
    EPILEPSIA, 2000, 41 : S86 - S90
  • [38] Rifaximin treatment in patients with severe alcoholic hepatitis: A multicenter, randomized controlled, open-label, pilot trial
    Song, Do Seon
    Yang, Jin Mo
    Jung, Young Kul
    Yim, Hyung Joon
    Kim, Hee Yeon
    Kim, Chang Wook
    Kim, Soon Sun
    Cheong, Jae Youn
    Lee, Hae Lim
    Lee, Sung Won
    Yoo, Jeong-Ju
    Kim, Sang Gyune
    Kim, Young Seok
    ANNALS OF HEPATOLOGY, 2025, 30 (01)
  • [39] Effects of Shenfu Injection in the Treatment of Septic Shock Patients: A Multicenter, Controlled, Randomized, Open-Label Trial
    Li, Yi
    Zhang, Xinchao
    Lin, Peihong
    Qiu, Haibo
    Wei, Jie
    Cao, Yu
    Pan, Shuming
    Walline, Joseph
    Qian, Chuanyun
    Shan, Zhigang
    Yu, XueZhong
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2016, 2016
  • [40] Nefazodone treatment of pathological gambling: A prospective open-label controlled trial
    Pallanti, S
    Rossi, NB
    Sood, E
    Hollander, E
    JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (11) : 1034 - 1039